NCT07751328Completed
Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device
Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable Magnetic Resonance Imaging Device The 'Portable MRI Study'
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 24 May 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Wellumio R&D Australia Pty Ltd
- Diseases
- Stroke
- NCT number
- NCT07751328
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 1 Jul 2024 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of a large metallic craniofacial implant, such as a bone fixation plate or mesh. Small metallic objects, such as aneurysm coils, are acceptable.
- Presence of an intracranial pressure monitor or another similar sensor that may compromise placement of the investigational device.
- Inability to wear the investigational device, including because of scalp skin lesions or previous intracranial surgery.
- History of a neurological condition, including brain tumour, previous stroke, or neurological trauma.
Other illness
- Contraindication to neuroimaging, including any condition that prohibits MRI.
- Any other condition or symptom that, in the investigator's judgement, prevents participation in the study.
- Post-study MRI findings indicating a brain condition associated with structural changes.
Other
- General:
- Pregnant or breastfeeding.
- Presence of an implanted electro-stimulating device in the head or neck.
- Unable to lie still for the duration of the scan.
- Unable to provide informed consent and, where applicable, consent cannot be obtained from a legally authorised representative.
- Healthy Participants:
Who the study is looking for
- Healthy Participants:
- Adults aged 18 years or older.
- Able to undergo an in-hospital MRI scan.
- Able to provide informed consent.
- Head size considered suitable for scanning with the Wellumio Axana brain scanner.
- Hospital Patients:
- Adults aged 18 years or older.
- Presenting to hospital with an acute neurological deficit suspected to be stroke within 24 hours of symptom onset.
- Clinical and radiological diagnosis of stroke, including ischemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage.
- Able to undergo an in-hospital MRI scan.
- Up to 72 hours post-acute stroke.
- Able to provide written informed consent or, where this is not possible, informed consent provided by a legally authorised representative.
- Head size considered suitable for scanning with the Wellumio Axana brain scanner.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Melbourne Hospital, also known as RMH Parkville Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.